{
    "nct_id": "NCT05319730",
    "official_title": "A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable esophageal squamous cell carcinoma (ESCC)\n* Has experienced investigator documented radiographic or clinical disease progression on one prior line of standard therapy, that includes a platinum agent and previous exposure to an anti-programmed cell death 1 (PD1)/programmed cell death ligand 1 (PD-L1) based therapy\n* Has an evaluable baseline tumor sample (newly obtained or archival) for analysis\n* Has adequately controlled blood pressure (BP) with or without antihypertensive medications\n* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Direct invasion into adjacent organs such as the aorta or trachea\n* Has experienced weight loss >10% over approximately 2 months prior to first dose of study therapy\n* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative therapy\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Active autoimmune disease that has required systemic treatment in past 2 years\n* Participants with human immunodeficiency virus (HIV) with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease\n* Concurrent active hepatitis B and hepatitis C virus infection\n* History of allogenic tissue/solid organ transplant\n* Clinically significant cardiovascular disease within 12 months from first dose of study intervention\n* Known gastrointestinal (GI) malabsorption or any other condition that may affect the absorption of lenvatinib. (Not applicable to actively enrolling arms as of Amendment 5)\n* Has risk for significant GI bleeding such as a serious nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to allocation/randomization, significant bleeding disorders, vasculitis, or has had a significant bleeding episode from the GI tract within 12 weeks prior to allocation/randomization. (Not applicable to actively enrolling arms as of Amendment 5)",
    "miscellaneous_criteria": "The main inclusion and exclusion criteria include but are not limited to the following:"
}